Distributor inventory | Tablet
Vildagliptin 50 mg + Metformin hydrochloride 850 mg (tablet)
Type 2 diabetes mellitus: to improve blood glucose control in adults when diet and exercise alone or single/dual therapy is inadequate.
Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin release and reducing glucagon. Metformin reduces hepatic glucose production and improves insulin sensitivity, lowering blood sugar without usually causing hypoglycaemia when used alone.
Take orally as advised by the doctor, usually with meals to reduce stomach upset. Swallow whole with water; do not crush/chew. Follow diet/exercise plan and monitor blood glucose regularly.
Common side effects of VILDAN-M 850 TAB may include:
Prescription medicine. Metformin may rarely cause lactic acidosis—risk increases with kidney impairment, dehydration, severe infection, heavy alcohol use, heart/respiratory failure; seek urgent care for rapid breathing, severe weakness, abdominal pain. Avoid/use with caution in renal impairment; periodic kidney function monitoring recommended. Temporarily stop metformin before/after iodinated contrast studies and major surgery as advised. Vildagliptin: monitor liver function; discontinue if jaundice or significant LFT elevation. Use caution in pancreatitis history; report severe abdominal pain. Not for type 1 diabetes or diabetic ketoacidosis.
